Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
BA1-M52H3 | Mouse | Human BACE-1 Protein, His Tag (active enzyme, MALS verified) | ![]() |
![]() ![]() |
|
BA1-H5213 | Human | Human BACE-1 Protein, Tag Free (active enzyme, MALS verified) | ![]() |
![]() ![]() |
|
BA1-H5261 | Human | Human BACE-1 Protein, Fc Tag | ![]() |
![]() ![]() |
|
BA1-H5220 | Human | Human BACE-1 Protein, His Tag (active enzyme, MALS verified) | ![]() |
![]() ![]() |
The purity of Human BACE-1 Protein, His Tag (Cat. No. BA1-M52H3) is more than 95% and the molecular weight of this protein is around 55-65 kDa verified by SEC-MALS.
The purity of Human BACE-1, Tag Free (Cat. No. BA1-H5213) is more than 90% and the molecular weight of this protein is around 55-65 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TAK-070 | TAK-070 | Phase 1 Clinical | Takeda | Alzheimer Disease | Details |
LY-2811376 | LY-2811376 | Eli Lilly And Company | Details | ||
Verubecestat | MK-8931; SCH-900931; J1I0P6WT7T (UNII code) | Merck Sharp & Dohme Corp | Details | ||
LY-3202626 | LY-3202626 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
Elenbecestat | E-2609; [14C]E2609 | Phase 3 Clinical | Eisai Co Ltd | Alzheimer Disease | Details |
Lanabecestat | AZD-3293; LY-3314814 | Phase 3 Clinical | Astrazeneca Pharmaceutical Co Ltd | Renal Insufficiency; Alzheimer Disease; Hepatic Insufficiency | Details |
This web search service is supported by Google Inc.